Abstract
We previously reported that treatment for schistosomiasis in persons infected with human immunodeficiency virus 1 (HIV-1) attenuated HIV replication as measured by plasma HIV RNA. We investigated systemic inflammation as measured by plasma levels of soluble tumor necrosis factor-alpha receptor II (sTNF-rII), interleukin-8, (IL-8), and IL-10 during schistosomiasis and HIV co-infection and after schistosomiasis treatment. The cohort was composed of 378 persons who were or were not infected with HIV-1, Schistosoma haematobium, or S. mansoni. Schistosomiasis-infected persons were randomized to receive praziquantel (40 mg/kg) at baseline or at the three-month follow-up. sTNF-rII and IL-8 were positively associated with schistosomiasis intensity as measured by circulating anodic antigen (CAA), regardless of HIV status. Interleukin-10 was positively associated with CAA in HIV-negative participants. IL-8 levels were higher in S. mansoni-infected individuals. Treatment for schistosomiasis caused a decrease in levels of sTNF-rII (P < 0.05) and IL-10 (P < 0.001). Our results indicate that schistosomiasis treatment may attenuate HIV replication by decreasing systemic inflammation.
| Original language | English |
|---|---|
| Journal | American Journal of Tropical Medicine and Hygiene |
| Volume | 79 |
| Issue number | 3 |
| Pages (from-to) | 331-7 |
| Number of pages | 7 |
| ISSN | 0002-9637 |
| Publication status | Published - Sept 2008 |
Keywords
- Adolescent
- Adult
- Cohort Studies
- Cross-Sectional Studies
- Cytokines
- Female
- HIV Infections
- HIV-1
- Humans
- Inflammation
- Interleukin-10
- Interleukin-8
- Male
- Middle Aged
- Praziquantel
- Receptors, Tumor Necrosis Factor, Type II
- Schistosomiasis
- Schistosomicides
- Zimbabwe
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
